Das metastasierte Prostatakarzinom: Therapieoptionen

Zusammenfassung

Für die Therapie des metastasierten hormonsensitiven und des kastrationsresistenten Prostatakarzinoms finden neben der medikamentösen Tumortherapie auch multimodale, interdisziplinäre Therapiekonzepte immer mehr Berücksichtigung. Für die Therapieentscheidung sind zahlreiche Faktoren relevant. Dieser Artikel beleuchtet die uroonkologische Therapiefindung für das metastasierte Prostatakarzinom (PC) aus medikamentöser und strahlentherapeutischer Sichtweise.

Publikationsverlauf

Artikel online veröffentlicht:
18. März 2025

• Literatur

• 1 Merseburger AS, Krabbe LM, Krause BJ. et al. The Treatment of Metastatic, Hormone-Sensitive Prostatic Carcinoma. Dtsch Arztebl Int 2022; 119 (37) 622-632
• 2 Sweeney CJ, Chen YH, Carducci M. et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 2015; 373 (8) 737-746
• 3 Fizazi K, Tran N, Fein L. et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2017; 377 (4) 352-360
• 4 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prostatakarzinom. Zu griff am 26.05.2024 unter https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/
• 5 Chi KN, Agarwal N, Bjartell A. et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2019; 381 (1) 13-24
• 6 Chi KN, Chowdhury S, Bjartell A. et al. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J Clin Oncol 2021; 39 (20) 2294-2303
• 7 Armstrong AJ, Azad AA, Iguchi T. et al. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 2022; 40 (15) 1616-1622
• 8 Fizazi K, Tran N, Fein L. et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castrationsensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019; 20 (5) 686-700
• 9 Smith MR, Hussain M, Saad F. et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med 2022; 386 (12) 1132-1142
• 10 Hussain M, Tombal B, Saad F. et al. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. J Clin Oncol 2023; 41 (20) 3595-3607
• 11 Hussain M, Mateo J, Fizazi K. et al. Survival with Olaparib in Metastatic Castration-resistant Prostate Cancer. N Engl J Med 2020; 383 (24) 2345-2357
• 12 Chi KN, Sandhu S, Smith MR. et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol 2023; 34 (9) 772-782
• 13 Saad F, Clarke NW, Oya M. et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, doubleblind, phase 3 trial. Lancet Oncol 2023; 24 (10) 1094-1108
• 14 Agarwal N, Azad AA, Carles J. et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 2023; 402: 291-303
• 15 Parker CC, James ND, Brawley CD. et al. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLoS Med 2022; 19 (6) e1003998
• 16 Bossi AFS, Maldonado X, Sargos P. et al. Prostate irradiation in men with de novo, lowvolume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2 × 2 design. JCO 2023; 41: LBA5000-LBA(2023)
• 17 Phillips R, Shi WY, Deek M. et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol 2020; 6 (5) 650-659
• 18 Holscher T, Baumann M, Kotzerke J. et al. Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P). Cancers (Basel) 2022; 14 (9) 2073
• 19 Alabi BR, Liu S, Stoyanova T. Current and emerging therapies for neuroendocrine prostate cancer. Pharmacol Ther 2022; 238: 108255
• 20 Fujimoto N, Tsubonuma Y, Nagata Y. et al. Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer. Anticancer Res 2023; 43 (9) 3841-3847